Merck & Co., Inc. (MRK)
Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma
Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss for its blockbuster therapy Keytruda.
Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns
The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.
Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports
Merck is nearing a roughly $6 billion all-cash deal to buy biotech firm Terns Pharma , the Financial Times reported on Tuesday, citing people familiar with the matter.
Merck (MRK) Exceeds Market Returns: Some Facts to Consider
Merck (MRK) reached $115.68 at the closing of the latest trading day, reflecting a +1.31% change compared to its last close.
Investors Buy Large Volume of Merck & Co., Inc. Call Options (NYSE:MRK)
Merck and Co., Inc. (NYSE: MRK - Get Free Report) saw unusually large options trading on Friday. Stock traders bought 672,962 call options on the company. This represents an increase of 1,339% compared to the average volume of 46,777 call options. Merck and Co., Inc. Stock Down 0.3% MRK opened at $115.61 on Friday. The company
Glenmede Investment Management LP Has $45.31 Million Stock Holdings in Merck & Co., Inc. $MRK
Glenmede Investment Management LP trimmed its stake in Merck and Co., Inc. (NYSE: MRK) by 14.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 539,875 shares of the company's stock after selling 89,706 shares during the quarter. Glenmede
Brown Brothers Harriman & Co. Purchases 7,463 Shares of Merck & Co., Inc. $MRK
Brown Brothers Harriman and Co. boosted its position in shares of Merck and Co., Inc. (NYSE: MRK) by 3.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 215,555 shares of the company's stock after buying an additional 7,463 shares
Merck & Co., Inc. $MRK is Arrowstreet Capital Limited Partnership’s 10th Largest Position
Arrowstreet Capital Limited Partnership cut its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 3.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,708,703 shares of the company's stock after selling 747,393 shares during
Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
Merck & Co., Inc. ( NYSE:MRK ) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14.
Merck (MRK) Rises Higher Than Market: Key Facts
The latest trading day saw Merck (MRK) settling at $117.11, representing a +1.14% change from its previous close.
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
